Press Releases
Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
January 7, 2016 Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer Breakthroughs 2020 Program Nation’s first insurance coverage of next generation whole genome sequencing and proteomic...
Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients
SEATTLE (August 5, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced an average survival increase of 11 months in end-stage colorectal cancer patients in Cancer Immunology,...
Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients
SEATTLE (August 5, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced an average survival increase of 11 months in end-stage colorectal cancer patients in Cancer Immunology,...
Etubics Adds Caskey, Paessler, Zeldis to Leadership Boards
SEATTLE – (July 20, 2015) - Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, has added Dr. Thomas Caskey to its Board of Directors and Drs. / Jerome Zeldis, Slobodan Paessler to its Scientific...
Gerald L. Messerschmidt Joins Etubics as Chief Medical Officer
SEATTLE – (July 9, 2015) - Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced today that it has retained Gerald L. Messerschmidt, MD, FACP as Chief Medical Officer. The company is...
Etubics Corporation Partners With the National Cancer Institute to Further Develop Therapeutic Cancer Vaccines
SEATTLE – (June 23, 2015) - Etubics Corporation, a privately held clinical stage biotechnology company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the...
Etubics Will Present Results of its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting In Chicago
Etubics and University of Texas Medical Branch Awarded Grant for Development of Universal Influenza Vaccine
SEATTLE (April 30, 2014) – Etubics Corporation, a Seattle based clinical stage biotechnology company focused on developing immunotherapeutics and vaccines with a proprietary platform that stimulates a long lasting “active” immune response, announced today that it has...
Etubics Awarded $1.5 Million Manufacturing Contract for Breast Cancer Immunotherapeutic
SEATTLE (September 26, 2013) – Etubics Corporation, a bio-pharmaceutical company with a proprietary vaccine platform that stimulates a long lasting "active" immune response, announced today that it has received a contract of approximately $1.5 million from Small...
Etubics Awarded Grant to Develop HPV Immunotherapy Targeting Head & Neck Cancer
SEATTLE (July 1, 2013) – Etubics Corporation, a bio-pharmaceutical company with a proprietary vaccine platform that stimulates a long lasting "active" immune response, announced today that it has received a grant of approximately $1.03 million from National Institute...